Notably, while Wegovy was first approved in June 2021, high out-of-pocket costs, sparse insurance coverage, and factory-related shortages likely limited how many eligible people could obtain these medications early on, which might help explain the delay in declining surgery rates
Mitrovi A, Brki P, Jovanovi T
Especially since GLP-1 agonists now have been shown to alter taste and tactile perception in some users
Although I do feel like I'm withering away." Anonymous, 45, female 16
The rise of GLP-1 RAs As a retinal specialist, many of your patients are already using GLP-1 RAs and many more will receive new prescriptions in the near future